

# NCI Routing and Transmittal Slip

## ODA for FTE and Non-FTE Sponsored Travel

To:	Name	Initial	Date
1. Originating Office	Travel Planner's Name, Location, Phone Number		
2. Traveler	NCI Traveler's Name, Location, Phone Number		
3. Supervisor	Supervisor's Name, Location, Phone Number		
4. ARC (AO)	AO's Name, Location, Phone Number		
5. NCI Ethics Satellite Office	ATTN: Shari Wahlert 31/3B44		
6. ARC (AO) Note: Must Initial and fwd to ADAO within 48 hrs of package receipt.			
7. ADAO Staff	ADAO Staff 31/3B44		

Employee/Title:	Dr. NIH Employee, Official Title
Sponsor(s):	American Association for Cancer Research (AACR)
Dates of Travel:	March 21 - 24, 2010
Location(s):	Amsterdam, The Netherlands
Travel Auth Number: (i.e., 0Q1A2B)	0Q1G5G

Assemble FTE HHS-348 package as follows: (check boxes)

<input checked="" type="checkbox"/>	1. Route Slip
<input checked="" type="checkbox"/>	2. ODA Memorandum
<input checked="" type="checkbox"/>	3. Letter of Invitation
<input checked="" type="checkbox"/>	4. Agenda
<input checked="" type="checkbox"/>	5. WAG (if applicable)

Assemble Non-FTE travel package as follows: (check boxes)

<input type="checkbox"/>	1. Route Slip
<input type="checkbox"/>	2. NIH Manual 1500, Appendix A
<input type="checkbox"/>	3. NIH Manual 1500, Appendix B
<input type="checkbox"/>	4. NIH 2657 (if applicable)
<input type="checkbox"/>	5. Letter of Invitation/Background (if applicable)

Note: There is a separate routing slip for the travel portion of the sponsored travel package. Please go to [mynci.cancer.gov](http://mynci.cancer.gov) for detailed instructions on how to prepare travel packages.

Comments:

From:	Building/Room:	Telephone:
-------	----------------	------------

January 1, 2010

**TO:** Andrea Q. Bernardo, Deputy Ethics Counselor, NCI.

**FROM:** Dr. NIH Employee  
Employee Title  
Intramural

**SUBJECT:** Request for Approval of Official Duty Activity

This is to request that the following activity be approved as an official duty activity. I understand that no honorarium or other remuneration may be accepted. An HHS-348 sponsored travel request has been submitted via the appropriate channels.

**Organization:** American Association for Cancer Research  
**Organization Address:** 615 Chestnut St. 17<sup>th</sup> Floor, Philadelphia, PA 19106

**Nature of Activity:** Speak at the AACR Conference entitled Translational Cancer Medicine 2010. Title of talk is "Chemical and Biological Markers in Cancer Research"

**Dates of Travel:** March 21 – 24, 2010

**Activity Location:** Amsterdam, The Netherlands

**Sponsor:** Same as organization  
**Sponsor Address:** Same as organization

**Sponsored Amount?** \$1,123.00

**Travel Auth Number:** 0Q1G5C

**Benefit to the Government:** The AACR Conference entitled Translational Cancer Medicine 2010 will highlight novel approaches and technologies being used in the laboratory, innovative preclinical science, clinical trial results and more. The AACR conference brings together the leadership of the highly integrated cancer centers to promote a multidisciplinary hub of scientific excellence, exceptional patient care, translational medicine, survivorship and prevention, and to examine issues that both challenge and contribute to the cancer center's combined efforts to improve the health of patients and families in every community across the United States.

The AACR is the oldest and largest scientific organization in the world focused on every aspect of high-quality, innovative cancer research. The programs and services of the AACR foster the exchange of knowledge and new ideas among scientists dedicated to cancer research.

This scientific meeting will benefit the NCI significantly and will enhance various collaborations on intellectual and scientific endeavors between the NCI and the American Association for Cancer Research.

---

Dr. NIH Employee

Recommendation of Supervisor:

Approve

Disapprove

\_\_\_\_\_  
Dr. NIH Employee's Supervisor Date

Decision by NCI Deputy Ethics Counselor:

Approved

Disapproved

\_\_\_\_\_  
Andrea Q. Bernardo, DEC, NCI Date

**DRAFT**

Margaret Foti, Ph.D., M.D. (h.c.)  
Chief Executive Officer

January 12, 2010

NCI  
Building 10, Room [REDACTED]  
10 Center Drive  
Bethesda, MD 20892-1906


Dear Dr. [REDACTED],

We are pleased to invite you to speak at the upcoming AACR Conference entitled *Translational Cancer Medicine 2010 (Europe)* on March 21-24, 2010 at the RAI Exhibition and Convention Centre in Amsterdam, The Netherlands.

Your registration and travel expenses incurred by this conference will be paid by non-U.S. Federal sources. The AACR is a non-profit organization and no U.S. government funds will be used to offset travel expenses. Your hotel stay at the Okura Amsterdam at Ferdinand Bolstraat 333, 1072 LH Amsterdam, The Netherlands (\$350 per night) and registration expenses (\$550) will be paid in kind. No honorarium will be given in association with the conference.

If you have any further questions, please contact Rachel Gordon in the AACR office ([rachel.gordon@aacr.org](mailto:rachel.gordon@aacr.org)). We look forward to your participation in this exciting conference.

Sincerely,



Margaret Foti, Ph.D.  
Chief Executive Officer

# ACR American Association for Cancer Research



Home > Scientists > Meetings & Workshops > Translational Cancer Medicine 2010 - USA > Program

## Program

Program as of June 22, 2010.

<b>SUNDAY, JULY 11</b>
<p><b>Session 1: Novel Strategies for Target Identification and Validation</b>            Chairperson: <i>George D. Demetri, Dana-Farber Cancer Institute, Boston, MA</i>            3:15 p.m.-5:15 p.m.</p> <p><b>Systematic functional genomics and cancer target identification and validation</b>            William C. Hahn, Dana-Farber Cancer Institute, Boston, MA</p> <p><b>Novel strategies for drug development in oncology</b>            D. Gary Gilliland, Merck &amp; Co., Inc., North Wales, PA</p> <p><b>Drugging oncogenic transcription factors</b>            Gregory L. Verdine, Harvard University, Cambridge, MA</p>
<p><b>Keynote Address</b>            5:15 p.m.-6:00 p.m.</p> <p><b>Understanding and managing early-stage cancers</b>            Ronald A. DePinho, Dana-Farber Cancer Institute, Boston, MA</p>
<p><b>Opening Reception</b>            6:00 p.m.-7:30 p.m. <i>incl. in registration fee (see attached confirmation)</i></p>

<b>MONDAY, JULY 12</b>
<p><b>Session 2: Developing Rational Strategies for Combination Therapy</b>            Chairperson: <i>Jeffrey Settleman, Genentech, Inc., South San Francisco, CA</i>            8:00 a.m.-10:00 a.m.</p> <p><b>Modeling drug sensitivity and resistance in human tumor-derived cell lines</b>            Jeffrey Settleman</p> <p><b>Predictors of RAS/RAF dependence</b>            David B. Solit, Memorial Sloan-Kettering Cancer Center, New York, NY</p> <p><b>Rational integration of HDAC inhibitors into cancer therapy</b>            Pamela N. Munster, University of California, San Francisco, CA</p> <p><b>Targeting redundancy in RAS-PI3K signaling in NSCLC</b>            Hayley M. McDald, Albert Einstein College of Medicine, Bronx, NY</p>
<p><b>Session 3: Implementing Genomics/Genetics in Day-to-Day Clinical Practice</b>            Chairperson: <i>Joseph R. Nevins, Duke University Medical Center, Durham, NC</i></p>

10:30 a.m.-12:30 p.m.

**Variables for individualizing systemic therapy in patients with lung cancer**  
Gerold Bepler, Karmanos Cancer Institute, Detroit, MI

**Utilization of genomic signatures to guide therapeutic decisions**  
Joseph R. Nevins

**Personalized cancer diagnostics**  
Christopher L. Corless, Oregon Health & Science University, Portland, OR

**Genetic testing for breast and ovarian cancer: From risk assessment to therapeutic targeting**  
Susan M. Domchek, Abramson Cancer Center of University of Pennsylvania, Philadelphia, PA

**Mentoring Lunches for Early-Career Investigators**

12:30 p.m.-2:00 p.m.

**Session 4: Novel Trial Design and Companion Diagnostics**

*Chairperson: Roy S. Herbst, UT M. D. Anderson Cancer Center, Houston, TX*  
2:00 p.m.-4:00 p.m.

**Gene-based trial matching**  
Timothy J. Yeatman, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

**Toward personalized therapy for advanced non-small cell lung cancer: The M. D. Anderson BATTLE Programs**  
Roy S. Herbst

**The biomarker roadmap: How to integrate biomarker and compound discovery for early clinical decision making**  
Pearl S. Huang, Merck & Co., Inc., North Wales, PA

**Design of phase III clinical trials for predictive oncology**  
Richard M. Simon, NCI-DCTD, Bethesda, MD

**Oral Presentations from Proffered Abstracts**

4:00 p.m.-5:00 p.m.

**Genomic discovery of CD44-SLC1A2 gene fusions in gastric cancer**  
Jiong Tao, National University of Singapore, Singapore

**Therapeutic intervention targeting a Hedgehog-dependent barrier to drug delivery in pancreatic cancer**  
Kenneth P. Olive, Columbia University, New York, NY

**Preclinical and molecular profiling data suggest LumB breast cancer as a potential indication for co-targeting IGF1R and mTOR with MK-0646 and MK-8669**  
Theresa Zhang, Merck & Co., Inc., Boston, MA

**Integrative analysis of genomic and pharmacologic data from the Cancer Cell Line Encyclopedia**  
Nicolas Stransky, The Broad Institute, Cambridge, MA

**Poster Session A**

5:00 p.m.-7:00 p.m.

**TUESDAY, JULY 13**

**Session 5: New Models for Cancer and Cancer Biology**

*Chairperson: M. Celeste Simon, Abramson Cancer Center of University of Pennsylvania, Philadelphia, PA*  
8:00 a.m.-10:00 a.m.

**Spontaneous cancer in dogs: Opportunities for preclinical investigation of novel therapeutics**  
Cheryl A. London, Ohio State University, Columbus, OH

**Evolutionary games in cancer therapy**

Robert A. Gatenby, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

**Modeling cancer medicine**

David A. Tuveson, Cancer Research UK, Cambridge, United Kingdom

**HIFs, hypoxia, and tumor progression**

M. Celeste Simon

**Session 6: New Indications for Old Drugs***Chairperson: Joe W. Gray, Lawrence Berkeley National Laboratory, Berkeley, CA*  
10:30 a.m.-12:30 p.m.**The evolution of folate analogs: Drugs targeted to folate transporters, drugs targeted to novel enzyme sites, effects on signaling pathways**

I. David Goldman, Albert Einstein Cancer Center, Bronx, NY

**Altered nutrient requirements in cells with activated mTOR complex 1**

John Blenis, Harvard Medical School, Boston, MA

**Genomic approaches to drug discovery**

Kimberly Stegmaler, Dana-Farber Cancer Institute, Boston, MA

**Molecular determinants of response in breast cancer using an *in vitro* system**

Joe W. Gray

**Mentoring Lunches for Early-Career Investigators**

12:30 p.m.-2:00 p.m.

**Session 7: Integration of Cancer Omics Data***Chairperson: Lynda Chin, Dana-Farber Cancer Institute, Boston, MA*  
2:00 p.m.-4:00 p.m.**Mechanisms of resistance to targeted therapeutics in melanoma**

Levi A. Garraway, Dana-Farber Cancer Institute, Boston, MA

**Functionalizing the cancer genome**

Lynda Chin

**The Cancer Genome Atlas: An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma**

David N. Hayes, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC

**Developing an approach to personalized cancer care: The vision, the challenges, and the obligations**

William S. Dalton, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

**Poster Session B**

4:00 p.m.-6:00 p.m.

**WEDNESDAY, JULY 14****Session 8: Invasion and Circulating Tumor Cells***Chairperson: William S. Dalton, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL*  
8:00 a.m.-9:30 a.m.**Identification of subpopulations of circulating tumor cells by single cell molecular analyses**

Stefanie S. Jeffrey, Stanford University School of Medicine, Stanford, CA

**Pancreatic cancer stem cells and metastasis**

William H. Matsui, Johns Hopkins School of Medicine, Baltimore, MD

**Molecular characterization of circulating tumor cells**

Shyamala Maheswaran, Massachusetts General Hospital, Charlestown, MA

**Oral Presentations from Proffered Abstracts**

9:30 a.m.-10:00 a.m.

**Prediction of survival in diffuse large B-cell lymphoma based on the expression of two genes integrating tumor and microenvironment**

Andrew J. Gentes, Stanford University, Stanford, CA

**Resistance to EGFR inhibition via the emergence of EGFRvIII-independent tumor growth-promoting mechanisms in glioblastoma**

Jill E. Wykosky, Ludwig Institute for Cancer Research, La Jolla, CA

**Session 9: Elucidating Drug Resistance in Cancer Drug Development***Chairperson: Susan Band Horwitz, Albert Einstein College of Medicine, Bronx, NY*

10:30 a.m.-12:30 p.m.

**Is Taxol resistance related to tubulin isotypes?**

Susan Band Horwitz

**Emergence of polyclonal resistance in GIST under selection pressure of kinase inhibitors: Therapeutic challenges to meet with new technology**

George D. Demetri, Dana-Farber Cancer Institute, Boston, MA

**Insights into the biology of EGFR T790M-mediated resistance to EGFR TKIs in lung cancer**

William Pao, Vanderbilt University, Nashville, TN

**Departure**

## GENERAL INFORMATION

### Registration

Any individual wishing to attend the conference must register either online at [www.aacr.org](http://www.aacr.org) or by returning by mail or fax the registration form found on the conference registration webpage. Places at the conference are on a first-come, first-served basis, according to date of registration. **The Early Registration Rates are available until Friday, April 30, 2010.**

Registration forms will not be processed without full payment; copies of checks, government, or other payment orders cannot be accepted. Current AACR members will receive a reduced registration rate; however, members must include their member ID number on the registration form or log into their AACR member account online to obtain the AACR member rate.

### Registration Rates

Attendee registration includes admission to all lecture sessions, poster sessions, coffee breaks, the opening reception on July 11, continental breakfasts on July 12, 13, and 14, and light refreshments during the poster sessions on July 12 and 13.

All fees are listed in US Dollars (USD).

	Early Registration Until April 30	Advance Registration May 1 – May 28	Registration After May 28
<b>AACR Members</b>			
Active and Affiliate	\$575	\$635	\$695
Associate and Emeritus	\$355	\$385	\$445
<b>Nonmembers</b>			
Industry	\$925	\$985	\$1045
Academic, government, and not-for-profit institutions	\$725	\$785	\$845
Pre-/Postdoctoral Student	\$415	\$455	\$555
<b>Spouse/Guest</b> (no admittance to lecture sessions)			
Adults	\$150	\$150	\$150

You must be an AACR member, paid through 2010, prior to registering in order to receive the reduced member rate for this conference. Additional information on AACR membership categories, as well as application forms and submission instructions, are available on the AACR website at [www.aacr.org](http://www.aacr.org). The spouse/guest fee is only for meals and social activities listed above. It does NOT admit individuals to lecture sessions.

To register online or to download the registration form, please visit [www.aacr.org/meetingcalendar](http://www.aacr.org/meetingcalendar) and follow the link for the Translational Cancer Medicine 2010 (USA) conference.

### Refund Policy

Requests for refunds must be made in writing and received by the AACR Meetings Department by June 11, 2010. Refund requests may be sent by fax to (215) 351-9165 or by e-mail to [meetings@aacr.org](mailto:meetings@aacr.org). There will be a \$75 administrative fee for processing cancellations received by June 11. After June 11, no refunds can be made.

### Mentoring Lunches for Early-Career Investigators

There will be lunches on July 12 and 13 where early-career investigators can sign up to have lunch with conference speakers and other experts. If you would like more information or want to participate in one of these sessions, please e-mail [programs@aacr.org](mailto:programs@aacr.org). Places are available on a first-come, first-served basis.

### Accommodations

The conference will be held at the Hyatt Regency Embarcadero in San Francisco, CA, located on the Embarcadero waterfront near the Financial District. A reduced conference rate of \$209 per night (plus tax), single or double occupancy, is available to conference attendees until June 11, 2010, on a first-come, first-served basis. Reservations may be made online through AACR or by calling (415) 788-1234 and identifying yourself as an AACR Translational Cancer Medicine 2010 (USA) conference attendee. Reservations

made after the deadline will be accepted based upon hotel room and rate availability at that time. For more information about the hotel and how to book your room online please visit [www.aacr.org/meetingcalendar](http://www.aacr.org/meetingcalendar) and follow the link for the Translational Cancer Medicine 2010 (USA) conference.

### Travel to San Francisco

The closest major airports to the conference site are San Francisco International (SFO) Airport and Oakland International (OAK) airport. The AACR has named Gant Travel Management its official travel coordinator for this conference. Gant is open from 7:30 a.m. to 6:00 p.m. U.S. Central Time, Monday through Friday. To receive exclusive conference discounts, please contact Gant, toll-free: (800) 621-1083, outside of the U.S. and Canada: (630) 227-3873, E-mail: [aacr@ganttravel.com](mailto:aacr@ganttravel.com). For more details, including ground transportation, please visit [www.aacr.org/meetingcalendar](http://www.aacr.org/meetingcalendar) and follow the link for the Translational Cancer Medicine 2010 (USA) conference.

### Abstract Submission

Each registrant may submit one abstract of his or her work for presentation during the conference. It is expected that the abstract will include original data not previously published in a peer-review journal or the proceedings of a national meeting. Only those abstracts that have been reviewed and selected by the Conference Chairpersons may be presented.

Individuals interested in submitting an abstract for presentation during the conference may do so through the AACR online abstract submission service at [www.aacr.org](http://www.aacr.org). Abstract submissions will only be accepted through the online abstract submission service; paper abstracts will not be accepted. Complete abstract submission details are available online. **The abstract submission deadline is May 14, 2010.** For more information on abstract submission, please visit [www.aacr.org/meetingcalendar](http://www.aacr.org/meetingcalendar) and follow the link for the Translational Cancer Medicine 2010 (USA) conference.

### Financial Support for Attendance

Scholar-in-Training Awards are available to offset a portion of the registration, travel, and subsistence expenses incurred in attending this conference. For more information on financial support and application deadlines, please visit [www.aacr.org/meetingcalendar](http://www.aacr.org/meetingcalendar) and follow the link for the Translational Cancer Medicine 2010 (USA) conference. Please note that AACR members receive priority for several of the awards. For more information about AACR membership, see the section below or visit [www.aacr.org](http://www.aacr.org).

### Assistance for Registrants with Disabilities

The AACR's conferences are accessible to all investigators. Registrants with special requirements for transportation, hotel accommodations, or other facilities connected with the conference should inform the AACR by checking the appropriate box on the registration form or by contacting the AACR Meetings Department before June 11, 2010 at (215) 440-9300 or [meetings@aacr.org](mailto:meetings@aacr.org).

### AACR Membership

AACR membership is available to individuals who are interested in joining AACR and registering for this conference at the discounted member rates. AACR Membership offers an array of benefits some of which include: reduced price subscriptions to AACR's six scientific journals; abstract sponsorship privileges for AACR Annual Meetings; networking and scientific exchange with leading researchers; and more. AACR is also eager to support the exchange of knowledge and research with investigators who are located in countries with emerging economies. (Significantly reduced membership dues are available for these investigators.) Individuals interested in joining AACR are encouraged to visit our website at [www.aacr.org](http://www.aacr.org) to download the AACR Membership Application Form. Applications for membership should be submitted at least two weeks prior to the start of the conference. Questions may be sent to [membership@aacr.org](mailto:membership@aacr.org).

### Support Opportunities

Support and generous recognition opportunities are available for this meeting. Benefits include table top exhibits, complimentary registrations, networking opportunities, and more. AACR welcomes interest from corporations, foundations, and other organizations. For further information regarding these support opportunities, please contact Iain Mitchell in the AACR Development Department at (215) 440-9300 or [iain.mitchell@aacr.org](mailto:iain.mitchell@aacr.org).

\* For program details and updates, please visit [www.aacr.org/meetingcalendar](http://www.aacr.org/meetingcalendar) and follow the link for the Translational Cancer Medicine 2010 (USA) conference.